Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR)

Tipranks - Tipranks - Wed Mar 18, 5:42AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rhythm Pharmaceuticals (RYTM – Research Report), Stryker (SYK – Research Report) and Esperion (ESPR – Research Report).

Claim 70% Off TipRanks Premium

Rhythm Pharmaceuticals (RYTM)

In a report released today, Michael Ulz from Morgan Stanley reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $136.00. The company’s shares closed last Monday at $90.51.

According to TipRanks.com, Ulz is a 3-star analyst with an average return of 0.9% and a 43.1% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Arrowhead Pharmaceuticals, and Zentalis Pharmaceuticals. ;'>

Rhythm Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $134.62, which is a 52.0% upside from current levels. In a report issued on March 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $131.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Stryker (SYK)

In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Stryker, with a price target of $450.00. The company’s shares closed last Monday at $349.56.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 2.4% and a 48.9% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Bausch + Lomb Corporation. ;'>

Stryker has an analyst consensus of Strong Buy, with a price target consensus of $431.85, which is a 26.8% upside from current levels. In a report issued on March 13, TipRanks – PerPlexity also upgraded the stock to Buy with a $400.00 price target.

Esperion (ESPR)

Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Esperion yesterday and set a price target of $1.78. The company’s shares closed last Monday at $2.69.

According to TipRanks.com, Zemansky is a 5-star analyst with an average return of 23.4% and a 59.5% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inhibikase Therapeutics, and Syndax Pharmaceuticals. ;'>

Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $7.30.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).